

Listing of Claims:

Claim 1 (currently amended) ~~Pharmaceutical compositions intended~~ A pharmaceutical composition for the treatment of urinary incontinence characterized in that they contain comprising oxybutynin as active ingredient, in combination or not with a moderated estrogen, in a mixture with ~~and~~ a pharmaceutically acceptable excipient or an inert vehicle, which is non-toxic, intended for vaginal route or rectal route administration.

Claim 2 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 1, characterized in that wherein oxybutynin is chosen selected from the group consisting of oxybutynin base, its addition salts with a mineral or organic acid and their epimers.

Claim 3 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 1, characterized in that wherein the moderated estrogen is chosen selected from the group formed by consisting of estriol, estradiol and esters, ethers and mixed ethers of estriol or and estradiol.

Claim 4 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 1, characterized in that they are formulated in the form of wherein it is selected from the form consisting of suppositories, suppositories, vaginal capsules, rectal capsules or and gels.

Claim 5 (currently amended) ~~Pharmaceutical compositions according to one of the preceding claims, characterized in that they contain~~ A pharmaceutical composition of claim 1 wherein it contains from 1 to 25 mg of oxybutynin or its salts.

Claim 6 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 5, characterized in that they contain wherein it contains from 5 to 15 mg of oxybutynin hydrochloride.

Claim 7 (currently amended) ~~Pharmaceutical compositions according to one of claims 1 to 6, characterized in that they contain~~ A pharmaceutical composition of claim 1 wherein it contains a dose of little resorbed moderated estrogen ranging from 0.01 to 5 mg per unit dose.

Claim 8 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 7, characterized in that wherein the moderated estrogen is estriol at a dose of 0.1 to 2 mg.

Claim 9 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 7 or claim 8, characterized in that wherein the unit dose of estriol ranges from 0.2 mg to 1 mg.

Claim 10 (currently amended) ~~Pharmaceutical compositions according to one of the preceding claims, characterized in that they also contain~~ A pharmaceutical composition of claim 1 wherein it contains one or more suspension agents.

Claim 11 (currently amended) Pharmaceutical compositions according to A pharmaceutical composition of claim 10, characterized in that wherein the suspension agent or agents are bioadhesive silicic acid derivatives and in particular the colloidal silica marketed under the trade name Aerasil®.

Claim 12 (currently amended) Pharmaceutical compositions according to one of the preceding claims, characterized in that A pharmaceutical composition of claim 1 wherein the excipient is a fatty phase formed by semisynthetic glycerides.

Claim 13 (currently amended) Pharmaceutical compositions according to A pharmaceutical composition of claim 11, characterized in that wherein the semisynthetic glycerides are those chosen from the products called Witepsol® and the products called or Suppocire®.

Claim 14 (currently amended) Pharmaceutical compositions according to one of the preceding claims characterized in that the formulations A pharmaceutical composition of claim 1 which also contain contains one or more gelling agents.

Claim 15 (currently amended) Pharmaceutical compositions according to A pharmaceutical composition of claim 14, characterized in that wherein the gelling agent or agents are cellulose derivatives and in particular alkylated and/or hydroxyalkylated cellulose derivatives.

Claim 16 (currently amended) ~~Pharmaceutical compositions according to A pharmaceutical composition of claim 14, in which wherein~~ the gelling agent is a carbomer.

Claim 17 (currently amended) ~~Pharmaceutical compositions according to A pharmaceutical composition of claim 16, in which wherein~~ the gelling agent is polycarbophil in acid form or in salified form.

Claim 18 (currently amended) ~~Pharmaceutical compositions according to A pharmaceutical composition of claim 16 or claim 17, in which wherein~~ the gelling agent is polycarbophil in the form of calcium salt.

Claim 19 (currently amended) ~~Pharmaceutical compositions according to one of the preceding claims, which bring about A pharmaceutical composition of claim 1 having~~ a sustained release of the active ingredients, spread over more than twenty four hours, ~~characterized in that wherein~~ the excipient is a fatty material in which the oxybutynin hydrochloride is placed in suspension.

Claim 20 (currently amended) ~~Pharmaceutical compositions according to one of the preceding claims A pharmaceutical composition of claim 1, allowing T maxs of oxybutynin to be obtained comprised between approximately two hours and approximately sixteen hours and preferably between six hours and twelve hours, characterized in that wherein~~ the excipient or the vehicle is ~~chosen selected~~ so that the speed of release is as long as possible.

Claim 21 (currently amended) ~~Pharmaceutical compositions according to one of the preceding claims, in which A pharmaceutical composition of claim 1 wherein~~ the excipient or the vehicle is ~~chosen~~ selected so that the administration of oxybutynin takes place once, or optionally twice, per twenty four hours.

Claim 22 (new) A method of treating urinary incontinency in humans comprising administering to humans in need thereof an amount of a composition of claim 1 sufficient to treat urinary incontinency.